Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery - Reuters

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQVGRLQTBxRHVVMUNsX05aYmd5akMtUmhuVzcxN0lEbF9yLW5CNmtSVFZVT2pCWDV5bS1zM3BobDd3dVU3cXJSdjhyTkZSWW1fNGpKYlhReFg3M3I3Zy14VE9WMWpnNDQ4QWt3Q0h0enZOcUNuX01HTVNrRkFZTlNTVUlqLWczZUlMbnBhWDRJY3drN3BuVDlQMm5tUEJuNTZwRTNsWk1mZlhqdTdwcXJ1eVYzQU9QUENMVGJrS0hSLW1IYjRy?oc=5" target="_blank">Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Isomorphic Labs, an AI-powered drug discovery spinoff from Google DeepMind, raised $2.1 billion led by Thrive Capital, after raising $600 million in its first round in March 2025.

Isomorphic Labs has raised $2.1 billion in a Series B financing led by Thrive Capital, with participation from the UK's Sovereign AI Fund, Abu Dhabi's MGX, Alphabet venture arm GV, and Singapore's Temasek.

Isomorphic Labs, the drug discovery company spun out of Google DeepMind in 2021, is in advanced discussions to raise more than $2 billion in a new funding round, according to Bloomberg.

Isomorphic Labs, an AI-driven drug discovery firm, has secured $2.1 billion in a Series B funding round led by Thrive Capital, with participation from Alphabet and other investors, to advance its AI drug design engine and in-house drug pipeline.

Isomorphic Labs, a subsidiary of Alphabet Inc., has raised $2.1 billion in its second round of outside capital, with new support from sovereign wealth funds, as it seeks to make artificial intelligence-designed drugs a reality.